A groundbreaking study has revealed that the high degree of variation in antibody immunity between individual people is a primary force in determining which strains of the influenza virus will ultimately come to dominate a population. The research, published as a Reviewed Preprint in the journal eLife, suggests that the collective "immune landscape" of a community is far more complex than previously understood, and that this individual-level diversity creates the specific evolutionary pressures that allow certain flu variants to spread while others fade away.
The study, which utilized a sophisticated high-throughput sequencing-based assay to quantify antibody immunity, focused specifically on the H3N2 influenza subtype. By examining the immune responses of both children and adults, the research team provided what eLife editors have described as a compelling and important advancement in the field of population-level immunity. The findings are expected to have significant implications for immunologists, virologists, and the researchers responsible for developing the annual vaccines that protect millions of people worldwide.
Influenza is a notoriously elusive pathogen, characterized by its ability to undergo "antigenic drift." This process involves the steady accumulation of genetic mutations that alter the virus’s surface proteins, particularly hemagglutinin (HA). Because HA is the primary target for the antibodies generated by the human immune system following an infection or vaccination, even minor changes in its structure can allow the virus to evade detection. This constant state of flux explains why individuals can be reinfected with the flu multiple times throughout their lives and why global health organizations must update vaccine compositions every year to match the circulating strains.
However, the human immune response is not a uniform shield. It is a highly personalized defense system shaped by an individual’s unique "immunological biography"—the specific history of every flu strain they have ever encountered and every vaccine they have ever received. This history creates a phenomenon where two people standing in the same room may have vastly different levels of protection against the same flu variant.
“Differences in infection and vaccination histories within a group of people mean that population immunity to a specific variant of the flu is highly varied,” explained co-lead author Caroline Kikawa, an MD/PhD student at the University of Washington and the Fred Hutch Cancer Center. Kikawa noted that while scientists have long suspected that this variety influences the virus’s evolution, proving it has been an uphill battle. Conventional methods for measuring antibody levels are often slow and labor-intensive, capable of processing only a few samples at a time, which makes it nearly impossible to map the immunity of a broad population in real-time.
To overcome these technical hurdles, Kikawa and co-lead author Andrea Loes, a Staff Scientist at the Fred Hutch Cancer Center, worked under the direction of senior author Jesse Bloom to develop a new high-throughput neutralization assay. This tool allows researchers to simultaneously measure how effectively individual serum samples—the antibody-rich component of the blood—can block infection across a wide array of different flu viruses.
The methodology involved the creation of a panel of viruses expressing 78 distinct hemagglutinin proteins, derived from flu strains that were circulating in 2023 as well as recent vaccine strains. To track these variants during the experiment, the team tagged each one with a unique genetic "barcode." By mixing these barcoded viruses with human sera and employing Illumina sequencing, the researchers could precisely quantify how well each individual’s antibodies neutralized each specific viral variant.
The scope of the study was extensive. Using 150 serum samples collected from children and adults in the United States during 2023, the team generated more than 11,000 individual neutralization titer measurements. A titer is a metric representing the concentration of antibodies in the blood; a higher titer indicates a stronger ability to neutralize a virus. This massive dataset provided a high-resolution snapshot of the American population’s immunity at the dawn of the 2023–2024 flu season.
The data revealed a striking level of individual variation. In the pediatric group, the responses were particularly diverse; some children possessed antibodies that could powerfully neutralize almost every strain tested, while others showed a significantly weaker or more specialized response. Adults tended to have more consistent levels of immunity across the board, likely due to a longer history of exposure and vaccination, yet even within the adult cohort, individual differences remained substantial.
Interestingly, the highest rates of neutralization were observed in a specific subset of children. This aligns with the long-standing "original antigenic sin" theory and the observation that immune responses are often most robust against the strains encountered during the first decade of life. Additionally, the researchers suggested that because children are frequently the primary drivers of flu transmission in communities, they may experience more frequent "immunological boosting" through repeated exposures, keeping their antibody levels high.
The core of the study, however, lay in connecting these individual immune profiles to the actual evolutionary success of the virus. To do this, the researchers utilized a statistical model known as multinomial logistic regression. This allowed them to compare their 11,000 titer measurements with the real-world growth rates of various flu strains throughout the 2023 season. By analyzing how the frequency of specific strains changed over time in the general population, they could see which variants were "winning" the evolutionary race.
The results were definitive: the flu strains that spread most successfully were those that managed to escape neutralization in a larger percentage of the individual serum samples. The model showed that a strain’s frequency in the population was likely to increase when a high fraction of individuals had antibody titers below a certain protective threshold. In other words, the virus finds the "holes" in the population’s collective immune net—not by looking at the average size of the holes, but by finding the specific gaps present in many individuals.
One of the most significant findings of the research was the failure of pooled serum samples to predict these evolutionary trends. In many current disease surveillance systems, researchers pool multiple blood samples together to create an "average" profile of population immunity. However, the study found that the relationship between neutralization levels and viral growth held true only when looking at individual samples. When the data was averaged out in a pool, the nuanced variation that drives viral success was lost. This suggests that current surveillance methods might be overlooking the very factors that allow new, dominant strains to emerge.
“Our findings show that individual-level immune variation, not just average immunity across the population, is a key factor in determining which flu strains are most successful,” said Andrea Loes. This insight could revolutionize how public health officials forecast flu seasons. If the "average" immunity of a population looks high, but a significant minority of individuals are completely unprotected against a specific variant, that variant still has a clear path to becoming a dominant strain.
Despite the depth of the data, the authors were careful to note certain limitations. The serum samples were obtained from a relatively narrow geographic range and specific age groups. Most of the pediatric samples were sourced from a hospital in Seattle, while the adult samples came from vaccinated groups in Philadelphia and Australia. This means the current dataset may not yet capture the full global spectrum of human immunity to the flu.
Nevertheless, the framework established by the Fred Hutch and University of Washington team represents a major leap forward. Jesse Bloom, a professor at Fred Hutch and an HHMI Investigator, emphasized the potential for this work to transform public health infrastructure. “This is nevertheless one of the largest datasets linking human antibody immunity to the success of flu virus strains in a population,” Bloom stated. He noted that the methodology provides a vital new lens for understanding how diverse immune histories influence viral evolution.
As global health organizations continue to refine their strategies for flu prevention, the ability to conduct large-scale, sequencing-based neutralization assays could become a cornerstone of viral surveillance. By providing a more detailed and individualized map of population immunity, these methods could offer the precision needed to better inform vaccine composition decisions, potentially leading to vaccines that are more closely tailored to the vulnerabilities of the population. The study serves as a reminder that in the ongoing battle against influenza, the most important data may not lie in the averages, but in the unique immune signatures of every individual.
